{
    "doi": "https://doi.org/10.1182/blood.V124.21.4900.4900",
    "article_title": "A T2* MRI Prospective Survey on Cardiac and Hepatic Iron in Non-Trasfusion-Dependent Thalassemia Intermedia Patients Treated with Desferrioxamine ",
    "article_date": "December 6, 2014",
    "session_type": "112. Thalassemia and Globin Gene Regulation",
    "abstract_text": "Background. In thalassemia intermedia (TI) patients no observational study prospectively evaluated in the real life the efficacy of the desferrioxamine (DFO) therapy in removing or preventing iron overload from the heart and the liver by T2* Magnetic Resonance Imaging (MRI). The efficacy endpoint of this study is represented by the changes in cardiac T2* and MRI LIC (liver iron concentration) values in non-transfusion dependent (NTD) TI patients after 18 months of desferrioxamine therapy. Methods. Among the 325 TI patients enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) network, we selected 129 TI patients NTD. We considered 29 patients who had been received DFO alone between the two MRI scans. Cardiac iron overload was assessed by the T2* multiecho technique. Hepatic T2* values were converted into liver iron concentration (LIC) values. Results. Mean age was 39.69 \u00b1 8.12 years and 14 (48.3%) patients were females. Patients started regular chelation therapy at a mean age of 21.92 \u00b1 15.89 years. The mean administered dosage of DFO via subcutaneous route was 38.46 \u00b1 10.27 mg/kg body weight on 3.32 \u00b1 1.54 days/week. The percentage of patients with excellent/good levels of compliance to the chelation treatment was 82.1%. At baseline only one patient showed cardiac iron overload (global heart T2*=15.23 ms) but he recovered at the FU (global heart T2*=26.93 ms). All patients without cardiac iron maintained the same status at the follow-up (FU). Eighteen patients (62.1%) had hepatic iron overload (MRI LIC \u22653 mg/g/dw) at the baseline. For this subgroup, the baseline and the FU LIC values were, respectively, 9.15 \u00b1 7.97 mg/g/dw and 7.41 \u00b1 6.28 mg/g/dw. The reduction in MRI LIC values was not significant (P=0.102). Out of the 11 patients with a baseline MRI LIC <3 mg/g/dw, only one (9.1%) showed hepatic iron at the FU. The Figure shows the evolution of different hepatic iron overload risk classes between the baseline and the FU. Conclusions. In this small population of sporadically or non transfused TI patients, DFO showed 100% efficacy in maintaining a normal global heart T2* value. As regards as the hepatic iron overload, the DFO therapy did not prevent the transition to a worst class in 2 patients. Figure 1 View large Download slide Figure 1 View large Download slide  Close modal Disclosures Pepe: Chiesi: Speakers Bureau; ApoPharma Inc.: Speakers Bureau; Novartis: Speakers Bureau.",
    "topics": [
        "deferoxamine",
        "iron",
        "magnetic resonance imaging",
        "thalassemia intermedia",
        "transverse spin relaxation time",
        "iron overload",
        "chelation therapy",
        "diagnostic imaging",
        "follow-up",
        "magnetic resonance imaging t2 mapping"
    ],
    "author_names": [
        "Antonella Meloni, PhD",
        "Aurelio Maggio, MD",
        "Carlo Cosmi, MD",
        "Alfonso D'Ambrosio, MD",
        "Elena Facchini, MD",
        "Roberta Chiari, MD",
        "Leonardo Sardella, MD",
        "Emanuele Grassedonio, MD",
        "Gianluca Valeri, MD",
        "Maria Giovanna Neri, PhD",
        "Vincenzo Positano, MSc",
        "Alessia Pepe, MD PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Antonella Meloni, PhD",
            "author_affiliations": [
                "Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Aurelio Maggio, MD",
            "author_affiliations": [
                "Ospedale, Palermo, Italy "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlo Cosmi, MD",
            "author_affiliations": [
                "AOU Sassari, Sassari, Italy "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alfonso D'Ambrosio, MD",
            "author_affiliations": [
                "AOU Senese - Policlinico S. Maria alle Scotte, Siena, Italy "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Elena Facchini, MD",
            "author_affiliations": [
                "Policlinico Universitario S. Orsola-Malpighi, Bologna, Italy "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberta Chiari, MD",
            "author_affiliations": [
                "Az. Osp. \u0093S. Maria\u0094, Terni, Italy "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Leonardo Sardella, MD",
            "author_affiliations": [
                "A.S.L. BA - Osp. \u0093Di Venere\u0094, Bari, Italy "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Emanuele Grassedonio, MD",
            "author_affiliations": [
                "Policlinico, Palermo, Italy "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gianluca Valeri, MD",
            "author_affiliations": [
                "Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Giovanna Neri, PhD",
            "author_affiliations": [
                "Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Vincenzo Positano, MSc",
            "author_affiliations": [
                "Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessia Pepe, MD PhD",
            "author_affiliations": [
                "Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-31T04:03:39",
    "is_scraped": "1"
}